Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Depreciation & Amortization (CF) (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $5.9 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 7.6% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $23.6 million, up 12.72%, while the annual FY2025 figure was $23.6 million, 12.72% up from the prior year.
  • Depreciation & Amortization (CF) reached $5.9 million in Q4 2025 per MRVI's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $6.0 million in Q3 2025 and bottomed at $1.1 million in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.6 million, with a median of $3.4 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 25.72% in 2021, then surged 130.1% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.1 million in 2021, then surged by 83.36% to $2.0 million in 2022, then surged by 100.51% to $3.9 million in 2023, then skyrocketed by 40.16% to $5.5 million in 2024, then increased by 7.6% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $5.9 million in Q4 2025, $6.0 million in Q3 2025, and $6.0 million in Q2 2025.